PCSK9 and hyperlipidemia: Studies into LDL receptor knockout mice have shown that Cyclosporine therapy leads to a rise in LDL Cholesterol, as well as an elevation of plasma PCSK9 levels suggesting that LDLr mediated lipoprotein clearance plays a protective role against Cyclosporine-mediated hyperlipidaemia and such imply that enhancing LDLr clearance with a PCSK9 inhibitor, might mitigate the effects of Cyclosporin [23].